Status:
COMPLETED
TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial
Lead Sponsor:
AstraZeneca
Conditions:
Hypertension
Eligibility:
All Genders
30-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine the effectiveness of candesartan cilexetil in preventing hypertension in people with high normal blood pressure. Patients will be randomized to either Candesa...
Eligibility Criteria
Inclusion
- Subjects between the ages of 30 and 65 (inclusive) at the time of the informed consent process
- have an average clinic BP in the high normal range of \< 139/85-89 mmHg or 130-139/\< 89 mm Hg (high normal BP range) (mean systolic and/or diastolic pressure based on 3 consecutive measurements) derived from the average of clinic visits 1,2 and 3.
Exclusion
- Have proteinuria \>1 + (by dipstick method)
- have a stroke, myocardial infarction (MI), transient ischemic attack (TIA), the presence of any clinically significant evidence of atherosclerosis or hypertensive target organ involvement or any significant medical condition that may compromise participation in this study.
Key Trial Info
Start Date :
July 1 1998
Trial Type :
INTERVENTIONAL
End Date :
October 1 2005
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00227318
Start Date
July 1 1998
End Date
October 1 2005
Last Update
August 30 2011
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Mobile, Alabama, United States
2
Research Site
Long Beach, California, United States
3
Research Site
Redondo Beach, California, United States
4
Research Site
Santa Ana, California, United States